FrancophonIA/ELRC3.0 huggingface dataset:
English: All components are for single use only.
Croatian: Sve su komponente samo za jednokratnu uporabu.
English: The safety and efficacy of Lucentis in children and adolescents below 18 years of age for indications other than retinopathy of prematurity have not been established.
Croatian: Sigurnost i djelotvornost Lucentisa u djece i adolescenata mlađih od 18 godina za druge indikacije osim retinopatije nedonoščadi nisu ustanovljene.
English: Mean change in visual acuity (letters) (SD)
Croatian: Srednja vrijednost promjene vidne oštrine (slova) (SD)
English: Cases of accidental overdose have been reported from the clinical studies in wet AMD and postmarketing data.
Croatian: Slučajevi slučajnog predoziranja prijavljeni su iz kliničkih ispitivanja kod vlažnog AMD-a i nakon stavljanja lijeka u promet.
English: Urinary tract infection*
Croatian: Infekcija mokraćnog sustava *
English: For CNV secondary to pathologic myopia (PM), many patients may only need one or two injections during the first year.
Croatian: Za CNV nastao kao posljedica patološke miopije (PM), mnogim bolesnicima će možda biti potrebna samo jedna ili dvije injekcije tijekom prve godine.
English: For women who wish to become pregnant and have been treated with ranibizumab, it is recommended to wait at least 3 months after the last dose of ranibizumab before conceiving a child.
Croatian: Ženama koje žele zanijeti, a liječene su ranibizumabom, ne preporučuje se zanijeti barem 3 mjeseca nakon zadnje doze ranibizumaba.
English: Lucentis has not been studied in patients who have previously received intravitreal injections, in patients with active systemic infections, or in patients with concurrent eye conditions such as retinal detachment or macular hole.
Croatian: Lucentis nije ispitivan u bolesnika koji su ranije dobivali intravitrealne injekcije te u bolesnika u kojih postoje aktivne sistemske infekcije, ili u bolesnika s istodobnim bolestima očiju poput ablacije mrežnice ili makularne rupe.
English: If patients are being treated according to a treat-and-extend regimen, once maximum visual acuity is achieved and/or there are no signs of disease activity, the treatment intervals can be extended stepwise until signs of disease activity or visual impairment recur.
Croatian: Ako se bolesnici liječe prema režimu „liječi i produži“ (engl. treat and extend), nakon što se postigne maksimalna oštrina vida i/ili nema znakova aktivnosti bolesti, intervali liječenja mogu se postupno produžiti dok se ne vrate znakovi aktivnosti bolesti ili oštećenja vida.
English: • sham injection at baseline, followed by an individualised treatment regimen driven by disease activity.
Croatian: • prividnu injekciju na početku, nakon čega slijedi individualizirani režim liječenja utvrđen na temelju aktivnosti bolesti.
English: One vial (type I glass) with a stopper (chlorobutyl rubber) containing 0.23 ml sterile solution.
Croatian: Jedna bočica (staklo tipa I) s čepom (klorobutilna guma) koja sadrži 0,23 ml sterilne otopine.
English: Patients should be informed of the symptoms of these potential adverse reactions and instructed to inform their physician if they develop signs such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in their vision, or increased sensitivity to light (see section 4.8).
Croatian: Bolesnike treba obavijestiti o simptomima tih potencijalnih nuspojava i uputiti da obavijeste svog liječnika ako se pojave znakovi poput boli u oku ili povećane nelagode, pogoršanja crvenila oka, zamagljenog ili smanjenog vida, povećanog broja malih čestica u vidnom polju ili povećane osjetljivosti na svjetlo (vidjeti dio 4.8).
English: Single dose of 0.5 mg/0.05 ml.
Croatian: Jednokratna doza od 0,5 mg/0,05 ml.
English: Available data in adolescent patients aged 12 to 17 years with visual impairment due to CNV are described in section 5.1.
Croatian: Dostupni podaci u bolesnika u dobi od 12 do 17 godina s oštećenjem vida uzrokovanim CNV-om opisani su u dijelu 5.1.
English: Renal impairment Dose adjustment is not needed in patients with renal impairment (see section 5.2).
Croatian: Oštećenje bubrega Bolesnicima s oštećenjem bubrega nije potrebno prilagoditi dozu (vidjeti dio 5.2).
English: Talk to your baby's doctor before your baby is given Lucentis.
Croatian: Obratite se liječniku Vašeg djeteta prije nego dijete primi Lucentis.
English: The side effects associated with the administration of Lucentis are either due to the medicine itself or the injection procedure and mostly affect the eye.
Croatian: Nuspojave povezane s primjenom Lucentisa uzrokovane su ili samim lijekom ili postupkom davanja injekcije i pretežno se javljaju u oku.
English: In the wet AMD phase III studies, the overall frequency of non-ocular haemorrhages, an adverse event potentially related to systemic VEGF (vascular endothelial growth factor) inhibition, was slightly increased in ranibizumab-treated patients.
Croatian: U ispitivanjima faze III kod vlažnog AMD-a, ukupna učestalost krvarenja koja nisu bila vezana uz oko kao štetnih događaja koje je bilo moguće povezati sa sustavnom VEGF (čimbenik rasta vaskularnog endotela) inhibicijom bila je blago povećana u bolesnika liječenih ranibizumabom.
English: In this study 277 patients were randomised in a 2:2:1 ratio to the following arms:
Croatian: U tom ispitivanju 277 bolesnika bilo je randomizirano u omjeru 2:2:1 u sljedeće skupine:
English: • a sterile pre-filled syringe in a sealed tray.
Croatian: • sterilnu napunjenu štrcaljku u zatvorenoj kaseti.
English: This swelling can be caused by diabetes (a disease called diabetic macular oedema (DME)) or by the blockage of retinal veins of the retina (a disease called retinal vein occlusion (RVO)).
Croatian: To oticanje može biti uzrokovano šećernom bolešću (bolest koja se naziva dijabetički makularni edem (DME)) ili začepljenjem retinalnih vena u mrežnici (bolest koja se naziva okluzija retinalne vene (RVO)).
English: The most common side effects in babies born prematurely are described below:
Croatian: Najčešće nuspojave u prijevremeno rođene dojenčadi opisane su u nastavku:
English: Based on analysis of population pharmacokinetics and disappearance of ranibizumab from serum for patients with neovascular AMD treated with the 0.5 mg dose, the average vitreous elimination half-life of ranibizumab is approximately 9 days.
Croatian: Na temelju analize populacijske farmakokinetike i uklanjanja ranibizumaba iz seruma bolesnika s neovaskularnim AMD-om liječenih dozom od 0,5 mg, prosječno poluvrijeme eliminacije ranibizumaba iz staklovine iznosi oko 9 dana.
English: Also, while a consistent effect was observed in subjects with subfoveal and juxtafoveal lesions, there are insufficient data to conclude on the effect of Lucentis in PM subjects with extrafoveal lesions.
Croatian: Također, iako je dosljedan učinak uočen u ispitanika s lezijama ispod fovee ili uz nju, nema dovoljno podataka da bi se mogao donijeti zaključak o učinku Lucentisa u ispitanika s PM-om i lezijama izvan fovee.
English: The extractable volume is not to be used in total.
Croatian: Ukupni volumen koji je moguće izvući ne smije se u cijelosti primijeniti.
English: Gain of ≥15 letters or BCVA ≥84 letters at Month 12 (%)
Croatian: Dobiveno ≥15 slova ili BCVA 84 slova u 12. mjesecu (%)
English: Table 8 Outcomes at Month 6 and 12 (BRAVO and CRUISE)
Croatian: Tablica 8 Ishodi nakon 6 i 12 mjeseci (ispitivanje BRAVO i CRUISE)
English: When comparing ranibizumab versus sham control at Month 2, a consistent treatment effect both overall and across baseline aetiology subgroups was observed:
Croatian: Kada se uspoređivao ranibizumab s placebo postupkom u kontrolnoj skupini nakon 2 mjeseca, bio je opažen dosljedan učinak liječenja kako ukupno tako i u podskupinama prema početnoj etiologiji:
English: After Lucentis treatment you may experience some temporary vision blurring.
Croatian: Nakon što primite Lucentis, vid Vam se može prolazno zamutiti.
English: Figure 1 Mean change in visual acuity from baseline to Month 24 in study FVF2598g (MARINA) and study FVF2587g (ANCHOR)
Croatian: Slika 1 Srednja vrijednost promjene vidne oštrine od početnog stanja do 24. mjeseca u ispitivanju FVF2598g (MARINA) i ispitivanju FVF2587g (ANCHOR)
English: - Do not use any pack that is damaged.
Croatian: - Ne koristiti ako je pakiranje oštećeno.
English: During the 24 weeks of the study, fewer patients in the ranibizumab 0.2 mg group switched to another treatment modality due to lack of response compared with the laser group (14.9% vs. 24.3%).
Croatian: Tijekom 24 tjedna ispitivanja manje je bolesnika u skupini koja je primala ranibizumab 0,2 mg prešlo na drugi način liječenja zbog izostanka odgovora u usporedbi sa skupinom koja je primala lasersku terapiju (14,9% u odnosu na 24,3%).
English: The majority of adverse reactions reported following administration of Lucentis are related to the intravitreal injection procedure.
Croatian: Većina nuspojava uočenih nakon primjene Lucentisa povezana je s postupkom primjene intravitrealne injekcije.
English: In this study, 225 patients were randomised in a 1:1:1 ratio to receive intravitreal ranibizumab 0.2 mg (n=74), 0.1 mg (n=77), or laser therapy (n=74).
Croatian: U ovom je ispitivanju 225 bolesnika bilo randomizirano u omjeru 1:1:1 na intravitrealno primanje ranibizumaba 0,2 mg (n=74), 0,1 mg (n=77) ili laserske terapije (n=74).
English: BRIGHTER was a 3-arm randomised active-controlled study that compared 0.5 mg ranibizumab given as monotherapy or in combination with adjunctive laser photocoagulation to laser photocoagulation alone.
Croatian: BRIGHTER je bilo aktivno kontrolirano randomizirano ispitivanje s 3 skupine u kojem se uspoređivalo 0,5 mg ranibizumaba primijenjenog kao monoterapija ili u kombinaciji s dodatkom laserske fotokoagulacije sa samom laserskom fotokoagulacijom.
English: Treatment of ROP in preterm infants
Croatian: Liječenje ROP-a u prijevremeno rođene dojenčadi
English: Following monthly intravitreal administration of Lucentis to patients with neovascular AMD, serum concentrations of ranibizumab were generally low, with maximum levels (Cmax) generally below the ranibizumab concentration necessary to inhibit the biological activity of VEGF by 50% (11-27 ng/ml, as assessed in an in vitro cellular proliferation assay).
Croatian: Nakon mjesečnih intravitrealnih primjena Lucentisa u bolesnika s neovaskularnim AMD-om, koncentracije ranibizumaba u serumu bile su općenito niske, a maksimalne razine (Cmax) bile su općenito ispod koncentracije ranibizumaba nužne za inhibiciju 50% biološke aktivnosti VEGF-a (11-27 ng/ml, procijenjeno testom stanične proliferacije in vitro).
English: Attach a 30G x ½″ sterile injection needle firmly onto the syringe by screwing it tightly onto the Luer lock (see Figure 4).
Croatian: Spojite sterilnu iglu za injekciju od 30G x ½″ čvrsto na štrcaljku tako što ćete je pričvrstiti na Luer zatvarač (vidjeti Sliku 4).
English: Post-inflammatory retinochoroidopathy 6.5 Central serous chorioretinopathy Idiopathic chorioretinopathy Miscellaneous aetiologies a a encompasses different aetiologies of low frequency of occurrence not included in the other subgroups
Croatian: Postupalna korioretinopatija Centralna serozna korioretinopatija Idiopatska korioretinopatija Razne etiologije a a obuhvaća različite etiologije niske učestalost pojavljivanja koje nisu uključene u ostale podskupine
English: In the pivotal study G2301 (MINERVA), five adolescent patients aged 12 to 17 years with visual impairment secondary to CNV received open-label treatment with ranibizumab 0.5 mg at baseline followed by an individualised treatment regimen as for the adult population.
Croatian: U ključnom ispitivanju G2301 (MINERVA), pet bolesnika adolescenata u dobi od 12 do 17 godina s oštećenjem vida uslijed CNV-a primilo je otvorenu terapiju ranibizumabom 0,5 mg na početku nakon čega je slijedio individualizirani režim doziranja kao za odraslu populaciju.
English: Leave the blunt filter needle in the vial and disconnect the syringe from the blunt filter needle.
Croatian: Tupu iglu s filterom ostavite u bočici, a štrcaljku odvojite od tupe igle s filterom.
English: The long-term (24 months) clinical safety and efficacy of Lucentis in patients with visual impairment due to macular oedema secondary to RVO were assessed in the BRIGHTER (BRVO) and CRYSTAL (CRVO) studies.
Croatian: Dugoročna (24-mjesečna) klinička sigurnost i djelotvornost Lucentisa u bolesnika s oštećenjem vida zbog makularnog edema uslijed RVO-a bile su procijenjene u ispitivanjima BRIGHTER (BRVO) i CRYSTAL (CRVO).
English: Angioid streaks
Croatian: Angioidne pruge
English: From Month 14 of the study, sham-treated patients were allowed to receive ranibizumab and from Month 19, more frequent treatments were possible.
Croatian: Od 14. mjeseca ispitivanja, bolesnici koji su samo prividno primali injekcije mogli su primiti ranibizumab, a od 19. mjeseca bilo je moguće češće liječenje.
English: Patients were treated with ranibizumab 0.5 mg pro re nata (PRN) in the same eye as the core study (D2301 RESTORE).
Croatian: Bolesnici su bili liječeni ranibizumabom 0,5 mg prema potrebi (p.p.) u isto oko kao u glavnom ispitivanju (D2301 RESTORE).
English: It is unknown whether Lucentis is excreted in human milk.
Croatian: Nije poznato izlučuje li se Lucentis u majčino mlijeko.
English: Upon monthly intravitreal administration of Lucentis 0.5 mg/eye, serum ranibizumab Cmax, attained approximately 1 day after dosing, is predicted to generally range between 0.79 and 2.90 ng/ml, and Cmin is predicted to generally range between 0.07 and 0.49 ng/ml.
Croatian: Procjenjuje se da pri mjesečnoj intravitrealnoj primjeni Lucentisa 0,5 mg/oku, Cmax ranibizumaba u serumu, postignut otprilike 1 dan nakon primjene doze, općenito iznosi od 0,79 do 2,90 ng/ml, a Cmin se općenito procjenjuje na 0,07 do 0,49 ng/ml.
English: At Month 2, all patients received open-label treatment with ranibizumab as needed.
Croatian: Nakon 2. mjeseca svi su bolesnici primali otvorenu terapiju ranibizumabom prema potrebi.
English: In adults transient increases in intraocular pressure (IOP) have been seen within 60 minutes of injection of Lucentis.
Croatian: U odraslih je bilo slučajeva prolaznih porasta intraokularnog tlaka (IOT) unutar 60 minuta nakon injekcije Lucentisa.
English: The mean average change in BCVA from Month 1 to Month 12 compared to baseline was +7.8 (±7.72) letters in the pooled ranibizumab-treated patients (n=102), compared to -0.1 (±9.77) letters for sham-treated patients; and the mean change in BCVA at Month 12 from baseline was 10.3 (±9.1) letters compared to -1.4 (±14.2) letters, respectively (p<0.0001 for the treatment difference).
Croatian: Srednja prosječna promjena BCVA od 1. mjeseca do 12. mjeseca u usporedbi s početnom vrijednošću bila je +7,8 (±7,72) slova u bolesnika liječenih ranibizumabom (n=102), u usporedbi sa -0,1 (±9,77) slova za prividno liječene bolesnike; a srednja promjena BCVA u 12. mjesecu u odnosu na početnu vrijednost bila je 10,3 (±9,1) slova u usporedbi s -1,4 (±14,2) slova (p<0,0001 za terapijsku razliku).
English: Carefully remove the cap from the injection needle without disconnecting the injection needle from the syringe.
Croatian: Pažljivo skinite zatvarač s igle za injekciju, a da pritom ne odvojite iglu za injekciju od štrcaljke.
English: The injection volume of 0.05 ml is then delivered; a different scleral site should be used for subsequent injections.
Croatian: Zatim se injicira volumen injekcije od 0,05 ml; za svaku sljedeću injekciju treba upotrijebiti drugo mjesto na bjeloočnici.
English: Patient-reported benefits were observed with ranibizumab treatment arms over vPDT (p-value <0.05) in terms of improvement in the composite score and several subscales (general vision, near activities, mental health and dependency) of the NEI VFQ-25.
Croatian: Koristi koje su prijavili bolesnici bile su uočene u skupinama koje su primale terapiju ranibizumabom u odnosu na vPDT (p-vrijednost <0,05) u smislu poboljšanja kompozitnog rezultata i na nekoliko podljestvica (opći vid, aktivnosti koje zahtijevaju vid na blizinu, mentalno zdravlje i ovisnost) upitnika NEI VFQ-25.
English: * The proportion of patients who did not require any ranibizumab treatment during the extension phase was 19%, 25% and 20% in the prior ranibizumab, prior ranibizumab + laser and prior laser groups, respectively.
Croatian: * Udio bolesnika kojima nije bilo potrebno liječenje ranibizumabom tijekom faze produžetka bio je 19% u skupini koja je prethodno primala ranibizumab, 25% u skupini s ranibizumabom + laserskom terapijom odnosno 20% u skupini s laserskom terapijom.
English: The patient's medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section 4.4).
Croatian: Prije provođenja intravitrealnog postupka treba pažljivo provjeriti bolesnikovu anamnezu s obzirom na reakcije preosjetljivosti (vidjeti dio 4.4).
English: • ranibizumab 0.5 mg at baseline, followed by an individualised dosing regimen driven by disease activity as assessed by visual acuity and/or anatomical parameters (e.g. VA impairment, intra/sub-retinal fluid, haemorrhage or leakage);
Croatian: • ranibizumab 0,5 mg na početku, nakon čega slijedi individualizirani režim doziranja utvrđen na temelju aktivnosti bolesti koja se procjenjuje s obzirom na vidnu oštrinu i/ili anatomske parametre (npr. oštećenje vidne oštrine, tekućina unutar ili ispod mrežnice, krvarenje ili propuštanje);
English: The clinical safety and efficacy of Lucentis 0.2 mg for the treatment of ROP in preterm infants have been assessed based on the 6-month data of the randomised, open-label, 3-arm, parallel-group superiority study H2301 (RAINBOW), which was designed to evaluate ranibizumab 0.2 mg and 0.1 mg given as intravitreal injections in comparison to laser therapy.
Croatian: Klinička sigurnost i djelotvornost Lucentisa 0,2 mg za liječenje ROP-a u prijevremeno rođene dojenčadi procjenjivane su na temelju 6-mjesečnih podataka iz randomiziranog, otvorenog ispitivanja superiornosti H2301 s 3 paralelne skupine (RAINBOW), koje je osmišljeno radi ocjenjivanja ranibizumaba 0,2 mg i 0,1 mg primijenjenog u obliku intravitrealne injekcije u usporedbi s laserskom terapijom.
English: The improvement of vision was accompanied by a stabilisation or reduction in central subfield thickness over the 12-month period.
Croatian: Poboljšanje vida bilo je popraćeno stabilizacijom ili smanjenjem centralne retinalne debljine tijekom 12-mjesečnog razdoblja.
English: What Lucentis is and what it is used for What you need to know before you are given Lucentis How Lucentis is given
Croatian: Što se nalazi u ovoj uputi Što je Lucentis i za što se koristi Što morate znati prije nego primite Lucentis Kako primjenjivati Lucentis Moguće nuspojave
English: In the phase II study D2201 (RESOLVE), 151 patients were treated with ranibizumab (6 mg/ml, n=51, 10 mg/ml, n=51) or sham (n=49) by monthly intravitreal injections.
Croatian: U ispitivanju faze II D2201 (RESOLVE), 151 bolesnik liječen je ranibizumabom (6 mg/ml, n=51, 10 mg/ml, n=51) ili prividno liječen (n=49), intravitrealnim injekcijama jednom mjesečno.
English: Rhegmatogenous retinal detachment or macular holes in adults
Croatian: Regmatogena ablacija mrežnice ili makularne rupe u odraslih
English: These diseases result from damage to the retina (light-sensitive layer at the back of the eye) caused by: - Growth of leaky, abnormal blood vessels.
Croatian: Te su bolesti rezultat oštećenja mrežnice (sloja u stražnjem dijelu oka koji je osjetljiv na svjetlost) uzrokovane: - Rastom propusnih, abnormalnih krvnih žila.
English: In a meta-analysis of these studies, 48.4% of the 315 patients with gradable DRSS scores in the subgroup of patients with moderately severe non-proliferative DR (NPDR) or worse at baseline experienced a ≥2-step improvement in the DRSS at Month 12 when treated with ranibizumab (n=192) vs 14.6% of patients treated with laser (n=123).
Croatian: U metaanalizi ovih ispitivanja, 48,4% od 315 bolesnika s ocjenjivim DRSS rezultatima u podskupini bolesnika s umjereno teškom ili težom neproliferativnom DR (NPDR) na početku, doživjelo je poboljšanje od ≥2 koraka u DRSS-u u 12. mjesecu kad su liječeni ranibizumabom (n=192) naspram 14,6% bolesnika koji su liječeni laserom (n=123).
English: How Lucentis works
Croatian: Kako Lucentis djeluje
English: Prior laser n=74
Croatian: Prethodni laser n=74
English: Retinal pigment epithelial tear
Croatian: Razderotina pigmentnog epitela mrežnice
English: Hold the syringe at eye level and carefully push the plunger until the edge below the dome of the rubber stopper is aligned with the dose mark (see Figure 7).
Croatian: Podesite dozu 11. Držite štrcaljku u razini očiju te pažljivo potisnite klip sve dok rub ispod kupole gumenog čepa ne bude u ravnini s oznakom za dozu (vidjeti Sliku 7).
English: Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of injection of Lucentis.
Croatian: Bilo je slučajeva prolaznih porasta intraokularnog tlaka (IOT) unutar 60 minuta nakon injekcije Lucentisa.
English: Each pre-filled syringe of 0.165 ml solution contains 1.65 mg of ranibizumab (10 mg/ml).
Croatian: Svaka napunjena štrcaljka s 0,165 ml otopine sadrži 1,65 mg ranibizumaba (10 mg/ml).
English: A total of 88 eyes (22.3%) had baseline DME: 42 (22.0%) and 46 (22.7%) eyes in the ranibizumab and PRP groups, respectively.
Croatian: Ukupno je 88 očiju (22,3%) imalo DME na početku: 42 (22,0%) u ranibizumab skupini i 46 (22,7%) očiju u PRP skupini.
English: A transient increase in post-dose intraocular pressure was observed following intravitreal injections, irrespective of dose.
Croatian: Nakon primjene intravitrealnih injekcija uočen je prolazan porast intraokularnog tlaka, neovisno o dozi.
English: Pack size of one pre-filled syringe, packed in a sealed tray.
Croatian: Veličina pakiranja je jedna napunjena štrcaljka, pakirana u zatvorenoj kaseti.
English: Pack containing one glass vial of ranibizumab with chlorobutyl rubber stopper.
Croatian: Pakiranje koje sadrži jednu staklenu bočicu ranibizumaba s čepom od klorobutilne gume.
English: Lucentis will be administered by an eye doctor as a single injection into your baby's eyes, usually under local anaesthetic.
Croatian: Lucentis primjenjuje liječnik za liječenje bolesti oka u obliku jednokratne injekcije u oči Vašeg djeteta, obično uz lokalni anestetik.
English: Intraocular pressure increased # Adverse reactions were defined as adverse events (in at least 0.5 percentage points of patients) which occurred at a higher rate (at least 2 percentage points) in patients receiving treatment with Lucentis 0.5 mg than in those receiving control treatment (sham or verteporfin PDT).
Croatian: Nuspojave su definirane kao štetni događaji (u najmanje 0,5 postotnih bodova bolesnika) koji su se javili s većom stopom (najmanje 2 postotna boda) u bolesnika koji su primali terapiju Lucentisom 0,5 mg nego u onih koji su primali kontrolnu terapiju (placebo postupak ili PDT verteporfinom).
English: Non-visual side effects include: Anxiety, nausea.
Croatian: Nuspojave koje nisu povezane s vidom uključuju: tjeskobu, mučninu.
English: In this study, the mean visual acuity change at year 2 was +2.7 letters in the ranibizumab group compared to -0.7 letters in the PRP group.
Croatian: U ovom je ispitivanju promjena u srednjoj vidnoj oštrini nakon 2 godine bila je +2,7 slova u grupi koja je primala ranibizumab u usporedbi s -0,7 slova u grupi liječenoj PRP-om.
English: In preterm infants treatment of ROP is initiated with a single injection per eye and may be given bilaterally on the same day.
Croatian: U prijevremeno rođene dojenčadi se liječenje ROP-a započinje jednom injekcijom po oku i može se primijeniti obostrano istoga dana.
English: For the intravitreal injection, a 30G x ½″ sterile injection needle should be used.
Croatian: Za primjenu intravitrealne injekcije mora se koristiti sterilna igla za injekciju od 30G x ½″.
English: Peel the lid off the syringe tray and, using aseptic technique, carefully remove the syringe.
Croatian: Odlijepite poklopac s kasete sa štrcaljkom i, koristeći aseptičnu tehniku,